Pα+ Psychedelic Bulletin #210: Compass Exec Defends Minimal Support Model in Stockholm; IV Ketamine Outperforms Esketamine Nasal Spray in Retrospective Study; Reunion Advances RE104 in Adjustment Disorder; Mindstate Wraps Phase I

I (Josh Hardman, the Editor) had a wonderful time in Stockholm last week for the Borealis Psychedelic Science Summit. While there was a great diversity of talks and discussions, for our purposes, I decided to focus this dispatch on two sessions: *** In a keynote titled “Can We Re-Medicalise the Psychedelic Experience?”, Compass’ Chief Medical Officer Guy Goodwin recounted some of…

Source